Cervera R . European Working Party on Systemic Lupus Erythematosus: Objectives and projects . Lupus1992; 1(Suppl 1): 29-29 .
2.
Cervera R , Khamashta MA , Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients . Medicine (Balt)1993; 72: 113–124 .
3.
Cervera R , Khamashta MA , Font J et al. Morbidity and mortality in systemic lupus erythematosus. A multicenter prospective study of 1,000 patients . Medicine (Balt)1999; 78: 167–175 .
4.
Galeazzi M , Morozzi G , Sebastiani GD et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies . Clin Exp Rheumatol1998; 16: 541–546 .
5.
Galeazzi M , Bellisai F , Sebastiani GD et al. Association of 16=6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients . Clin Exp Rheumatol1998; 16: 717–720 .
6.
Sebastiani GD , Galeazzi M , Tincani A et al. Anticardiolipin and anti-b2GPI antibodies in a large series of European patients with systemic lupus erythematosus . Scand J Rheumatol1999; 28: 344–351 .
7.
Galeazzi M , Annunziata P , Sebastiani GD et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations . J Rheumatol2000; 27: 135–141 .
8.
Galeazzi M , Sebastiani GD , Tincani A et al. HLA class II alleles associations of anticardiolipin and anti-b2GPI antibodies in a large series of European patients with systemic lupus erythematosus . Lupus2000; 9: 47–55 .
9.
Houssiau F , Vasconcelos C , De Ram ónE et al. A low-dose IV cyclophosphamide therapy, followed by azathioprine is as effective as high-dose regimen in inducing initial short-term response in proliferative lupus nephritis . Arthritis Rheum1997; 40(Suppl): S324-S324 .
